The Swiss pharma firm Roche is creating an oral GLP-1 weight reduction drug.
An analyst at Deutsche Financial institution not too long ago referenced a drug as a risk to Eli Lilly's competing therapy.
The...
By Maggie FickLONDON (Reuters) -Novo Nordisk on Wednesday trimmed its full-year income outlook after reporting weaker-than-expected quarterly product sales of its widespread weight-loss drug Wegovy, stirring worries amongst patrons about stiffening rivals from...
The Mobil emblem and gasoline costs are displayed at a Mobil gasoline station in Los Angeles on Oct. 28, 2022.Mario Tama | Getty PhotographsTake a look at the businesses making headlines in premarket...
Whereas Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) will seemingly rule the weight problems drug marketplace for the following decade, rivals equivalent to Amgen (NASDAQ:AMGN) and Pfizer (NYSE:PFE) might quickly be...
